Chinese drugmaker Sinopharm said that its mRNA COVID-19 vaccine against the Omicron variant has received government approval on Thursday to begin clinical trials.
The company has built a 2 billion dose annual capacity production line in Shanghai and will continue to study the vaccine's efficacy.
Copyright © 2020 CGTN. Beijing ICP prepared NO.16065310-3